Hiv Epidemic Control

DENVER — Giving patients the option of choosing long-acting PrEP resulted in a fivefold increase in coverage and a reduction in HIV incidence during the SEARCH trial in Uganda, researchers reported.

Researchers found that implementing generic PrEP programs for young men who have sex with men at risk for HIV — a group known to have adherence and engagement issues — would reduce new infections and be cost-effective.

The federal court ruling against requiring health care insurers to cover PrEP could result in more than 2,000 new and preventable HIV infections among at-risk populations within 12 months of the ruling.

Roughly 20 million people with HIV in 54 countries are receiving ART through the President's Emergency Plan for AIDS Relief, a 300-fold increase in 2 decades, according to a new report.

Despite some progress being made, sub-Saharan Africa remained a hot spot for new HIV infections, with approximately 689,000 new infections annually among HIV-negative adults between 2015 and 2019, according to data pooled from 15 countries.

Long-acting cabotegravir and rilpivirine dosed every 8 weeks was effective and well tolerated, showing noninferiority to the standard 4-week dosing at 152 weeks, according to extended data from the ATLAS-2M trial.

The introduction of long-acting injectable cabotegravir PrEP in sub-Saharan Africa could result in fewer future AIDS deaths and new infections, while being a cost-effective alternative to oral PrEP, according to a recent study.

Women who experienced physical or sexual intimate partner violence, or both, in the past year were more likely to acquire HIV and less likely to be virally suppressed, according to a study published in The Lancet HIV.

HIV testing fell by almost one-third in the early months of the COVID-19 pandemic, and prescriptions for PrEP also were negatively affected, according to data published in MMWR.

On Thursday, experts, clinicians and researchers across the world acknowledged World AIDS Day, celebrated each year on December 1.